Hepatitis Monthly

Published by: Kowsar

Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients

Hong Deng 1 , * , Chun-Ling Wang 1 , 2 , Jing Lai 1 , Su-Lin Yu 1 , Dong-Ying Xie 1 and Zhi-Liang Gao 1
Authors Information
1 Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 Department of Hepatology, Huizhou Municipal Central Hospital, Hui Zhou, China
Article information
  • Hepatitis Monthly: September 01, 2016, 16 (9); e40263
  • Published Online: July 24, 2016
  • Article Type: Research Article
  • Received: June 23, 2016
  • Accepted: June 28, 2016
  • DOI: 10.5812/hepatmon.40263

To Cite: Deng H, Wang C, Lai J, Yu S, Xie D, et al. Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients, Hepat Mon. 2016 ; 16(9):e40263. doi: 10.5812/hepatmon.40263.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Liaw YF, Chu CM. Hepatitis B virus infection. The Lancet. 2009; 373(9663): 582-92
  • 2. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167-85[DOI][PubMed]
  • 3. Chinese Society of H, Chinese Society of Infectious Diseases CMA. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2011; 32(4): 405-15[PubMed]
  • 4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1)[DOI][PubMed]
  • 5. Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007; 13(47): 6419-24[PubMed]
  • 6. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005; 43(3): 508-14[DOI][PubMed]
  • 7. Fan JG, Chitturi S. Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol. 2008; 23(5): 679-81[DOI][PubMed]
  • 8. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009; 50(1): 204-10[DOI][PubMed]
  • 9. Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014; 59(10): 2571-9[DOI][PubMed]
  • 10. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon. 2011; 11(2): 103-6[PubMed]
  • 11. Mao Y, Huang J. Commentary on: Aspartate transaminase to platelet ratio index (APRI): A simple noninvasive index assessing liver fibrosis in patients with chronic liver diseases. Hepat Mon. 2011; 11(5): 376-7[PubMed]
  • 12. Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf). 2013; 1(1): 19-26[DOI][PubMed]
  • 13. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat. 2012; 19(4): 244-53[DOI][PubMed]
  • 14. Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2014; 29(7): 1470-6[DOI][PubMed]
  • 15. Ledinghen V, Wong GL, Vergniol J, Chan HL, Hiriart JB, Chan AW, et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016; 31(4): 848-55[DOI][PubMed]
  • 16. Yuan L, Shao J, Hao M, Li C, Wang G, Wang T, et al. [Correlation between liver hardness testing results obtained by FibroTouch and FibroScan and liver pathological stage]. Zhonghua Gan Zang Bing Za Zhi. 2014; 22(6): 425-9[DOI][PubMed]
  • 17. Ou X, Wang X, Wu X, Kong Y, Duan W, Zhou J, et al. [Comparison of FibroTouch and FibroScan for the assessment of fibrosis in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2015; 23(2): 103-6[DOI][PubMed]
  • 18. Wang R, Ren W, Zhao S, Niu X, Tan P, Du H, et al. [Clinical study on FibroTouch and multi-parameter model for diagnosis of hepatic fibrosis in patients with chronic liver disease]. Zhonghua Gan Zang Bing Za Zhi. 2015; 23(4): 265-9[DOI][PubMed]
  • 19. Mao CS, B NH, Yin H. The value of FibroTouch fat attenuation parameter in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease. Chin J Infect Dis. 2015; 33(6): 339-42
  • 20. Li JB, liu S, Wen B, Gao N, Wang BY. Clinical significance of FibroTouch, ultrasound, and computed tomography in diagnosis of fatty liver disease: a comparative analysis . J Clin Hepatol. 2016; 32(3): 459-62
  • 21. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(3): 531-61[DOI][PubMed]
  • 22. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6): 2005-23[DOI][PubMed]
  • 23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6): 1313-21[DOI][PubMed]
  • 24. Scheuer PJ, Standish RA, Dhillon AP. Scoring of chronic hepatitis. Clin liver Dis. 2002; 6(2): 335-47
  • 25. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29(12): 1705-13[PubMed]
  • 26. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014; 39(3): 254-69[DOI][PubMed]
  • 27. Kumar M, Rastogi A, Singh T, Behari C, Gupta E, Garg H, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol. 2013; 28(7): 1194-201[DOI][PubMed]
  • 28. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010; 36(11): 1825-35[DOI][PubMed]
  • 29. Macaluso FS, Maida M, Camma C, Cabibbo G, Cabibi D, Alduino R, et al. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. J Hepatol. 2014; 61(3): 523-9[DOI][PubMed]
  • 30. Shen F, Zheng R, Mi Y, Shi J, Chen G, Chen J, et al. [A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver]. Zhonghua Gan Zang Bing Za Zhi. 2014; 22(12): 926-31[DOI][PubMed]
  • 31. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 2005; 4: 10[DOI][PubMed]
  • 32. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33[DOI][PubMed]
  • 33. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010; 42(7): 503-8[DOI][PubMed]
  • 34. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137(3): 865-72[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments